VERNON, BC, December 15, 2021 /CNW/ – Dosology Sciences Inc. (CSE: MOOD) (“Doseology” or the “Company”), a British ColumbiaMontreal-based diversified life sciences company, which plans to develop mental health therapies using natural psilocybin treatments, officially announces the addition of Dr. Olivier Wellman-Labadie to its growing team of mycologists and researchers.
dr. Olivier Wellman-Labadie, Ph.D. has been a Dosage Counselor and is the Qualified Responsible Person (QPIC) for the company’s Drug and Controlled Substance Dealer License Application. In his role as QPIC, he will perform the duties required by Health Canada’s Controlled Drugs and Substances Dealer License and assist in the development of psilocybin research and mushroom production.
Dr. Wellman-Labadie holds a doctorate in molecular biology from the University of Ottawa (2008), and an MBA with a specialization in Marketing and Pharmaceutical Management from the University Laval (2009). He also earned a bachelor’s degree in pharmacy from the University of British Columbia (2014) and is a licensed pharmacist in British Columbia. Since 2007, he has co-authored twelve research articles in the field of molecular biology.
Dr. Wellman-Labadie’s experience as a licensed pharmacist and former research associate at University of Ottawa gives him extensive experience in the efficient operation of laboratories and pharmacological facilities, and his seven years of experience in managing professional teams will also greatly benefit the Company in his new role. Her dedication to her community practice in British Columbia gave him a deep understanding of the challenges faced by diverse populations, including helping patients with mental health and addiction issues.
With significant research and laboratory experience, Dr. Wellman-Labadie will directly contribute to Doseology’s near-term goal of increasing the production of high-quality mushrooms and psilocybin products for research purposes. He will play a leading role in establishing a research center for the analysis of psilocybin, psilocin and medicinal mushrooms, and in developing standard operating procedures for extraction and analysis. psilocybin and psilocin. Additionally, he will help expand the scientific team of experts, liaise with academic research partners, and initiate a psychedelic research program.
Dr. Wellman-Labadie released the following statement regarding his role at the company:
I am thrilled to join Doseology in supporting their mission to fight our mental health pandemic through Canada, United States, and all over the world. Serving my community to provide care to vulnerable populations, I have witnessed profound mental wellness challenges that Doseology is now addressing. Doseology’s innovative therapies and new products will make a difference in the lives of so many people, enabling them to heal and thrive. Like Alexander Fleming would say, “The unprepared mind cannot see the outstretched hand of opportunity.
In November, Doseology completed its application to Health Canada to become an “Authorized Distributor” under the Controlled Drugs and Substances Act (Canada). The license, which has a standard application processing time of 270 days, would allow Doseology to produce, possess, process, sell, ship, transport and deliver psychedelic compounds, including psilocybin and mushroom psilocin.
The Company’s development roadmap includes the production of new strains of magic mushrooms, sales to authorized parties and potential new therapeutic applications. Through its functional mushroom products and planned psychedelic therapy solutions, Doseology is able to improve the lives of people around the world by restoring mental health and potentially treating serious health conditions as people grow. such uses are approved.
Learn more about Doseology Science’s mushroom research and production at doseology.com.
On behalf of the Board of Directors
Chairman and Chief Executive Officer and Director
Dosology Sciences Inc.
About Doseology Sciences Inc.
Doseology Sciences Inc. (CSE: MOOD) is a British Columbiadiversified life sciences company, whose mission is to reinvent mental health therapies through innovation, technology and sustainability. With a focus on psychedelic and non-psychedelic compounds, Doseology will offer cutting-edge therapeutic products and services, with the goal of having a meaningful impact on the mental health pandemic and improving overall health.
This corporate update contains statements that constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is often identified by the words “may”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, ” wait” or similar expressions. Readers are cautioned that forward-looking information is not based on historical facts, but rather reflects the Company’s management’s expectations, estimates or projections regarding the business of future results or events of the Company based on opinions, management’s assumptions and estimates considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in financial markets; declines in prevailing prices for products in the markets in which the Company operates; adverse changes in applicable laws or adverse changes in the application or enforcement of applicable laws; regulations and enforcement priorities of governmental authorities; compliance with government regulations and related costs; and other risks described in the Prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may differ materially from those described herein as anticipated, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be those anticipated, estimated or planned. The Company does not intend and undertakes no obligation to update this forward-looking information, except as otherwise required by applicable law.
No securities regulatory authority has approved or disapproved of the contents of this press release. The securities of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities law, and may not be offered or sold in United States, or to or for the account or benefit of any person in United States, lack of registration or applicable exemption from registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities of United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.
CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Dosology Sciences inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2021/15/c6395.html